Elizabeth I. Buchbinder, MD

Elizabeth I. Buchbinder, MD

Medical Oncology

Contact Information

Office Phone Number

617-632-5055

Fax

617-632-6727

Appointments

877-332-4294

Researcher

Physician

Senior Physician
Assistant Professor of Medicine, Harvard Medical School

Clinical Interests

Immunotherapy, Melanoma, Targeted therapies

Diseases Treated

Board Certification

  • Internal Medicine
  • Medical Oncology

Fellowship

  • Beth Israel Deaconess Medical Center, Medical Oncology

Residency

  • Beth Israel Deaconess Medical Center, Internal Medicine

Medical School

  • Tufts University School of Medicine

Publications

    • Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. Cancers (Basel). 2024 Jan 24; 16(3). View in: Pubmed

    • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb 17; 403(10427):632-644. View in: Pubmed

    • Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Cancer Immunol Immunother. 2024 Jan 18; 73(1):17. View in: Pubmed

    • Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer. Semin Arthritis Rheum. 2024 Feb; 64:152335. View in: Pubmed

    • Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell Melanoma Res. 2023 Nov; 36(6):542-556. View in: Pubmed

    • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023 10; 11(10). View in: Pubmed

    • Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature. Adv Radiat Oncol. 2024 Jan; 9(1):101310. View in: Pubmed

    • Exploring Influencing Factors of Anxiety Improvement Following Mindfulness-Based Music Therapy in Young Adults with Cancer. J Music Ther. 2023 Jun 03; 60(2):131-148. View in: Pubmed

    • A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma. Invest New Drugs. 2023 08; 41(4):551-555. View in: Pubmed

    • Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy. J Immunother. 2023 06 01; 46(5):192-196. View in: Pubmed

    • A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. Invest New Drugs. 2023 Jun; 41(3):365-370. View in: Pubmed

    • Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 06 15; 129(12):1904-1918. View in: Pubmed

    • Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023 May; 5(5):e274-e283. View in: Pubmed

    • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 02; 388(9):813-823. View in: Pubmed

    • Exploring Young Adults' Perspectives of Participation in a Mindfulness-Based Music Therapy Intervention Before and During the COVID-19 Pandemic. J Adolesc Young Adult Oncol. 2023 08; 12(4):569-576. View in: Pubmed

    • Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260. View in: Pubmed

    • Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders. Front Immunol. 2022; 13:1069444. View in: Pubmed

    • Evolving Management of Stage IV Melanoma. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e397478. View in: Pubmed

    • Impact of Precision Medicine in Oncology: Immuno-oncology. Cancer J. 2023 Jan-Feb 01; 29(1):15-19. View in: Pubmed

    • Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer. 2023 03; 181:188-197. View in: Pubmed

    • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023 02 01; 129(3):367-375. View in: Pubmed

    • Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma. JAAD Case Rep. 2022 Sep; 27:162-166. View in: Pubmed

    • Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022 09; 33(9):968-980. View in: Pubmed

    • Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv. 2022 Apr 29; 8(17):eabl6339. View in: Pubmed

    • Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653. View in: Pubmed

    • Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022 02; 162:22-33. View in: Pubmed

    • Cancer Therapy Targeting CD47/SIRPa. Cancers (Basel). 2021 Dec 11; 13(24). View in: Pubmed

    • Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer. J Pain Symptom Manage. 2022 Apr; 63(4):e357-e363. View in: Pubmed

    • Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. J Immunother Cancer. 2021 11; 9(11). View in: Pubmed

    • Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318. View in: Pubmed

    • Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study. J Am Acad Dermatol. 2022 08; 87(2):403-406. View in: Pubmed

    • Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 04; 10(8):2627-2635. View in: Pubmed

    • A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654. View in: Pubmed

    • Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Aug; 70(8):2209-2221. View in: Pubmed

    • Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525. View in: Pubmed

    • Immune Checkpoint Therapies for Melanoma. Hematol Oncol Clin North Am. 2021 02; 35(1):99-109. View in: Pubmed

    • Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. Sci Rep. 2020 10 16; 10(1):17536. View in: Pubmed

    • Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011. View in: Pubmed

    • Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. View in: Pubmed

    • Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Manag. 2020 Jun 15; 7(2):MMT41. View in: Pubmed

    • Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 09; 16(9):e933-e942. View in: Pubmed

    • Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311. View in: Pubmed

    • Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurg. 2020 07; 139:226-231. View in: Pubmed

    • The Evolution of Adjuvant Therapy for Melanoma. Curr Oncol Rep. 2019 11 25; 21(12):106. View in: Pubmed

    • A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019 08; 25(8):1243-1250. View in: Pubmed

    • Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. View in: Pubmed

    • Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49. View in: Pubmed

    • Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. Melanoma Res. 2019 02; 29(1):70-76. View in: Pubmed

    • Immunotherapy Toxicity. Hematol Oncol Clin North Am. 2019 04; 33(2):275-290. View in: Pubmed

    • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: Pubmed

    • Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. View in: Pubmed

    • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. View in: Pubmed

    • Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res. 2017 12; 5(12):1133-1140. View in: Pubmed

    • An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221. View in: Pubmed

    • Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. View in: Pubmed

    • Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. View in: Pubmed

    • The Phoenix Rises: The Rebirth of Cancer Immunotherapy. Clin Chem. 2017 07; 63(7):1190-1195. View in: Pubmed

    • Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221. View in: Pubmed

    • Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. View in: Pubmed

    • Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017 01; 40(1):31-35. View in: Pubmed

    • A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050. View in: Pubmed

    • A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52. View in: Pubmed

    • Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393. View in: Pubmed

    • Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul; 17(7):943-955. View in: Pubmed

    • Biomarkers in Melanoma: Lessons from Translational Medicine. Trends Cancer. 2016 06; 2(6):305-312. View in: Pubmed

    • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. View in: Pubmed

    • CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb; 39(1):98-106. View in: Pubmed

    • Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol. 2016 Feb; 13(2):77-8. View in: Pubmed

    • Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. View in: Pubmed

    • Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis. J Cutan Pathol. 2016 Jan; 43(1):57-63. View in: Pubmed

    • Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015 Sep; 125(9):3377-83. View in: Pubmed

    • Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15. View in: Pubmed

    • Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. Clin Ther. 2015 Apr 01; 37(4):755-63. View in: Pubmed

    • Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. View in: Pubmed

    • Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am. 2014 Jun; 28(3):571-83. View in: Pubmed

    • Parents' experience of their child's first psychiatric breakdown: "welcome to hell". Soc Work Health Care. 2013; 52(6):538-57. View in: Pubmed

    • Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7. View in: Pubmed

    • Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012 Nov-Dec; 35(9):711-5. View in: Pubmed

    • Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e615-22. View in: Pubmed

    • Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108. View in: Pubmed

    • Signaling between focal adhesion kinase and trio. J Biol Chem. 2003 Apr 11; 278(15):13265-70. View in: Pubmed

    Locations

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Elizabeth I. Buchbinder, MD

    About Our Ratings

    Physician Star Rating Comment Block

    Discovery and Insights